Decreased pituitary response to insulin-induced hypoglycaemia in young lean male patients with essential hypertension

Journal of Human Hypertension

Volumn 20, Issue 7, 2006, Pages 510-516

  Radikova, Zofia ^a,c   Penesova, A ^a   Cizmarova, E ^b   Huckova, M ^a   Kvetnansky, R ^a   Vigas, M ^a   Koska, J ^a  

^a INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^b Department of Cardiology   (Slovakia)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

ACTH; Catecholamines; Growth hormone; Hypoglycaemia; Prolactin

Indexed keywords

ALDOSTERONE; CATECHOLAMINE; CORTICOTROPIN; GROWTH HORMONE; HYDROCORTISONE; HYPOPHYSIS HORMONE; INSULIN; NORADRENALIN; PROLACTIN; RENIN;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; HUMAN; HYPOPHYSIS; INSULIN HYPOGLYCEMIA; INSULIN TOLERANCE TEST; MALE; PLASMA RENIN ACTIVITY; SYMPATHETIC TONE;

ADULT; ALDOSTERONE; BLOOD GLUCOSE; BLOOD PRESSURE; CASE-CONTROL STUDIES; EPINEPHRINE; GROWTH HORMONE; HEART RATE; HUMANS; HYPERTENSION; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; NOREPINEPHRINE; PITUITARY GLAND; RENIN; THINNESS;

EID: 33745257566     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002026     Document Type: Article

References (51)

1. Julius S. Borderline hypertension. Clin Exp Hypertens 1999; 21: 741-747.
2. Svetkey LP. Management of prehypertension. Hypertension 2005; 45: 1056-1061.
3. Amerena J, Julius S. The role of the autonomic nervous system in hypertension. Hypertens Res 1995; 18: 99-110.
4. Rose KM, North K, Arnett DK, Ellison RC, Hunt SC, Lewis CE et al. Blood pressure and pulse responses to three stressors: Associations with sociodemographic characteristics and cardiovascular risk factors. J Hum Hypertens 2004; 18: 333-341.
5. Touyz RM, Campbell N, Logan A, Gledhill N, Petrella R, Padwal R. Canadian Hypertension Education Program: The 2004 Canadian recommendations for the management of hypertension: Part III - Lifestyle modifications to prevent and control of hypertension. Can J Cardiol 2004; 20: 55-59.
6. Elenkov IJ, Wilder RL, Chrousos GP, Vizi S. The sympathetic nerve - an integrative interface between two supersystems: The brain and the immune system. Pharmacol Rev 2000; 52: 595-638.
7. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002; 53: 865-871.
8. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983; 5: 86-99.
9. DeQuattro V, Feng M. The sympathetic nervous system: The muse of primary hypertension. J Hum Hypertens 2002; 16(Suppl 1): S64-S69.
10. Al-Damluji S, Francis D. Activation of central alpha 1-adrenoceptors in humans stimulates secretion of prolactin and TSH, as well as ACTH. Am J Physiol 1993; 264(2 Part 1): E208-E214.
11. Kiem DT, Barna I, Koenig JI, Makara GB. Adrenocorticotropin, prolactin and beta-endorphin stimulatory action of alpha-2-adrenoceptor antagonists. Neuroendocrinology 1995; 61: 152-158.
12. Vigas M, Kvetnansky R, Jurcovicova J, Jezova D, Tatar P. Comparison of catecholamine and adenopituitary hormone responses to various stress stimuli in man. In: Usdin E, Kvetnansky R and Axelrod J (eds). Stress: The Role of Catecholamines and Other Neurotransmitters. Gordon and Breach Science Publishers: New York, 1984, 865-882.
13. Pacak K, Palkovits M. Stressor specificity of central neuroendocrine responses: Implications for stress-related disorders. Endocr Rev 2001; 22: 502-548.
14. European Society of Hypertension - European Society of Cardiology Guidelines Committee. European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27: S5-S10.
16. Peuler JD, Johnson GA. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 1977; 21: 625-636.
17. Carrasco GA, Van De Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol 2003; 463: 235-272.
18. De Kloet RE. Hormones, brain and stress. Endocr Regul 2003; 37: 51-68.
19. Jezova D, Makatsori A, Duncko R, Moncek F, Jakubek M. High trait anxiety in healthy subjects is associated with low neuroendocrine activity during psychosocial stress. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1331-1336.
20. Muller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev 1999; 79: 511-607.
21. Al-Damluji S. Adrenergic control of the secretion of anterior pituitary hormones. Baillieres Clin Endocrinol Metab 1993; 7: 355-392.
22. Tatar P, Vigas M. Role of alpha 1- and alpha 2-adrenergic receptors in the growth hormone and prolactin response to insulin-induced hypoglycemia in man. Neuroendocrinology 1984; 39: 275-280.
23. Bolli GB, Fanelli CG. Physiology of glucose counter-regulation to hypoglycemia. Endocrinol Metab Clin North Am 1999; 28: 467-493.
24. Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the thresholds for symptoms. J Clin Invest 1987; 79: 777-781.
25. Mitrakou A, Ryan C, Veneman T, Mokan M, Jenssen T, Kiss I et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms and cerebral dysfunction. Am J Physiol Endocrinol Metab 1991; 260: E67-E74.
26. Kinsley BT, Levy CJ, Simonson DC. Prolactin and beta endorphin responses to hypoglycemia are reduced in well-controlled insulin-dependent diabetes mellitus. Metabolism 1996; 45: 1434-1440.
27. Giustina A, Doga M, Bossoni S, Bodini C, Legati F, Pizzocolo G et al. Central alpha-2 adrenergic function in patients with essential hypertension. Horm Metab Res 1990; 22: 451-452.
28. Julius S, Nesbitt S. Clinical consequences of the autonomic imbalance in hypertension and congestive heart failure. Scand Cardiovasc J Suppl 1998; 47: 23-30.
29. Schlaich MP, Lambert E, Kaye DM, Krozovski Z, Campbell DJ, Lambert G et al. Sympathetic augmentation in hypertension: Role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 2004; 43: 169-175.
30. Esler M, Lux A, Jennings G, Hastings J, Socratous F, Lambert G. Rilmenidine sympatholytic activity preserves mental stress, orthostatic sympathetic responses and adrenaline secretion. J Hypertens 2004; 22: 1529-1534.
31. Frey MJ, Lanoce V, Molinoff PB, Wilson JR. Skeletal muscle beta-receptors and isoproterenol-stimulated vasodialtation in canine heart failure. J Appl Physiol 1989; 67: 2026-2031.
32. Hayes MJ, Qing F, Rhodes CG, Rahman SU, Ind PW, Sriskandan S et al. In vivo quantification of human pulmonary beta-adrenoreceptors: Effect of beta-agonist therapy. Am J Resp Crit Care Med 1996; 154: 1277-1283.
33. Beau SL, Tolley TK, Saffitz JE. Heterogeneous transmural distribution of beta-adrenergic receptor subtypes in failing human hearts. Circulation 1993; 88: 2501-2509.
34. DeRosa MA, Cryer PE. Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab 2004; 287: E32-E41.
35. Eide I, Kolloch R, DeQuattro V, Miano L, Dugger R, Van der Meulen J. Raised cerebrospinal fluid norepinephrine in some patients with primary hypertension. Hypertension 1979; 1: 255-260.
36. Kawano Y, Fukiyama K, Takeya Y, Abe I, Omae T. Catecholamines, angiotensin II and odium concentrations in cerebrospinal fluid in young men with borderline hypertension. Clin Exp Hypertens A 1984; 6: 1131-1145.
37. Cubeddu LX, Hoffman IS. Cerebrospinal fluid norepinephrine levels in essential hypertension: Effects of drug treatment and withdrawal. J Cardiovasc Pharmacol 1987; 10(Suppl 12): S205-S210.
38. Lambert GW, Ferrier C, Kaye DM, Kalff V, Kelly MJ, Cox HS et al. Monnaminergic neuronal activity in subcortical brain regions in essential hypertension. Blood Pressure 1994; 3: 55-66.
39. Lambert GW, Ferrier C, Kaye DM, Jennings GL, Kalff V, Kelly MJ et al. Central nervous system norepinephrine turnover in essential hypertension. Ann NY Acad Sci 1995; 763: 679-694.
40. Tan Y, Gan Q, Knuepfer MM. Central alpha-adrenergic receptors and corticotrophin releasing factor mediate hemodynamic responses to acute cold stress. Brain Res 2003; 968: 122-129.
41. Tsuda K, Tsuda S, Nishio I. Role of alpha-2-adrenergic receptors and cyclic adenosine monophosphate-dependent protein kinase in the regulation of norepinephrine release in the central nervous system of spontaneously hypertensive rats. J Cardiovasc Pharmacol 2003; 42(Suppl 1): S81-S85.
42. Barbieri C, Ferrari C, Caldara R, Curtarelli G. Growth hormone secretion in hypertensive patients: Evidence for a derangement in central adrenergic function. Clin Sci (London) 1980; 58: 135-138.
43. Alba-Roth J, Losa M, Spiess Y, Schopohl J, Muller OA, von Werder K. Interaction of clonidine and GHRH on GH secretion in vivo and in vitro. Clin Endocrinol (Oxford) 1989; 30: 485-491.
44. Cella SG, Morgese M, Mantegazza P, Muller EE. Inhibitory action of the alpha 1-adrenergic receptor on growth hormone secretion in the dog. Endocrinology 1984; 114: 2406-2408.
45. Jezova-Repcekova D, Klimes I, Jurcovicova J, Vigas M. Effect of adrenergic receptor blockade on cortisol and GH response to insulin-induced hypoglycemia in man. Int J Clin Pharmacol Biopharm 1979; 17: 64-67.
46. Karhuvaara S, Kallio A, Koulu M, Scheinin H, Scheinin M. No involvement of alpha 2- adrenoceptors in the regulation of basal prolactin secretion in healthy men. Psychoneuroendocrinology 1990; 15: 125-129.
47. Krulich L, Jurcovicova J, Le T. Prolactin (PRL) release-inhibiting properties of the alpha 2 adrenergic receptor antagonist idazoxan: comparison with yohimbine. Life Sci 1989; 44: 809-818.
48. Kapoor R, Chapman IM, Willoughby JO. Alpha 2 and beta adrenoceptors in the mediobasal hypothalamus and alpha 2 adrenoceptors in the preoptic-anterior hypothalamus stimulate prolactin secretion in the conscious male rat. J Neuroendocrinol 1993; 5: 189-193.
49. Jurcovicova J, Le T, Krulich L. The paradox of alpha 2 adrenergic regulation of prolactin (PRL) secretion. I. The PRL-releasing action of the alpha 2 receptor agonist. Brain Res Bull 1989; 23: 417-424.
50. Jurcovicova J, Le T, Krulich L. The paradox of alpha 2 adrenergic regulation of prolactin (PRL) secretion. II. The PRL-releasing action of the alpha 2 receptor antagonists. Brain Res Bull 1989; 23: 425-432.
51. Cuneo RC, Livesey JH, Nicholls MG, Espiner EA, Donald RA. Effects of alpha-2 adrenoreceptor blockade by yohimbine on the hormonal response to hypoglycaemic stress in normal man. Horm Metab Res 1989; 21: 33-36.